Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gynecologic 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 2Stomach Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Ovarian Neoplasms 1Metastatic Castrate Resistant Prostate Cancer 1Liver Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Gemcitabine 43pembrolizumab 36Paclitaxel 36Nivolumab 31Docetaxel 29Capecitabine 29Bevacizumab 29Oxaliplatin 28Fluorouracil 28Cisplatin 26Leucovorin 24Cyclophosphamide 23Radiosurgery 20Irinotecan 20Carboplatin 20aldesleukin 19Cetuximab 19Interleukin-2 16fludarabine phosphate 15fludarabine 15Pemetrexed 15Trastuzumab 14Magnetic Resonance Spectroscopy 14Ipilimumab 14Fulvestrant 14130-nm albumin-bound paclitaxel 14Prednisone 13Everolimus 13Radiotherapy 12Panitumumab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasm Metastasis × tasquinimod × Clear all
NCT02057666 2021-04-23

TasQ003

Ipsen

Phase 3 Terminated
146 enrolled 13 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT01743469 2019-01-08

A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers

Ipsen

Phase 2 Completed
201 enrolled 23 charts
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Liver Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡